以阳性和阴性症状量表(PANSS)评定临床疗效,以副反应量表(TESS)评定不良反应。
The efficacy was evaluated by positive and negative symptom scale(PANSS), and the side effects by treatment emergent symptom scale(TESS).
方法采用随机对照方法,以马普替林为对照组,应用HAMD、HAMA、TESS量表,在疗前、疗后1、2、4、6周进行疗效及副反应评定。
Methods the patients were randomly assigned into venlafaxine and maprotiline group and tested with HAMD, HAMA and TESS at the time of weeks 1, 2, 4, 6 weeks after treatment.
在治疗前,治疗后4、8和12周末分别以阻性症状和阴性症状量表(PANSS)和副反应量表(TESS)评定疗效和副作用。
The efficiency and side effects were assessed with the postive and negative symptom scale (PANSS)and treatment emergent symptom seale (TESS) before and 4,8and 12 weekends after the treatment.
采用阳性症状量表和阴性症状量表(PANSS)以评定齐拉西酮对女性精神分裂症的疗效,采用不良反应量表(TESS)评定该药物的副反应。
The positive and negative symptom scale (PANSS) is adopted to appraise the curative effect, and the treatment emergent symptom scale (TESS) is adopted to appraise by-reaction.
采用阳性症状量表和阴性症状量表(PANSS)以评定齐拉西酮对女性精神分裂症的疗效,采用不良反应量表(TESS)评定该药物的副反应。
The positive and negative symptom scale (PANSS) is adopted to appraise the curative effect, and the treatment emergent symptom scale (TESS) is adopted to appraise by-reaction.
应用推荐